HCW Biologics
HCWB · listed on Nasdaq · worth $6.3 million
Five insider buys in the last year, $510K in all. None in the last two weeks.
Green dot = an insider bought◆ = company newsA number = that many on nearby days · click a mark to see who, or read the filing
Reverse split 1-for-6 in Jun 2026. When a company does a reverse split, the chart rewrites its old prices to look far bigger than they really were — so the high early prices here aren't what HCWB ever actually traded at. The drop is real, but those huge old numbers aren't.
Company insiders
In the last year, four insiders bought HCW Biologics stock and none sold.
How each buyer's earlier purchases went: the stock about six months later, beside the S&P 500 over the same days. Purchases planned in advance are left out. Past results, not a forecast.
Director
Scott T. Garrett
Bought $250K on May 22 — 177,936 shares at $1.41, held through a trust or family, 88% of what they now own.
Chief Executive Officer
Hing C. Wong
Bought $160K on May 22 — 113,879 shares at $1.41, 19% of what they now own.
Chief Financial Officer
Rebecca Byam
Bought $20K on May 22 — 14,235 shares at $1.41, 25% of what they now own.
All reports
Every insider trade and SEC report we hold for HCW Biologics.
Analysts, earnings and news
Analysts' price target
1 analyst
Analysts' opinions, which tend to run optimistic. Not our forecast or advice.
Profit vs what was expected